2cureX AB Logo

2cureX AB

Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.

2CUREX | ST

Overview

Corporate Details

ISIN(s):
SE0010468124
LEI:
549300SFOL75WIYF2O80
Country:
Sweden
Address:
Box 159, 261 22 Landskrona
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

2cureX AB is a biotechnology company specializing in precision oncology through functional drug sensitivity testing. The company develops and commercializes the IndiTreat® family of tests, its core product line. IndiTreat® is the first CE-marked in-vitro diagnostic (IVD) test that utilizes patient-derived 3D tumoroids to predict individual responses to cancer treatments. This technology provides oncologists with personalized data to guide therapy selection, particularly for patients with metastatic colorectal cancer. The company's mission is to improve cancer treatment outcomes by matching specific therapies to individual patients, thereby enhancing the efficacy of oncological care.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all 2cureX AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for 2cureX AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for 2cureX AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Genome&Company Logo
Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.
South Korea 314130
Develops molecular diagnostics using DNA methylation biomarkers for early cancer detection.
South Korea 228760
Genomtec S.A. Logo
Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.
Poland GMT
GENOTECH CORP. Logo
A biotech firm offering gene synthesis, genome analysis, and biopharmaceutical products globally.
South Korea 066830
Gentian Diagnostics ASA Logo
Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.
Norway GENT
GI Innovation Inc. Logo
Develops fusion protein biologics for oncology, allergic, and metabolic diseases.
South Korea 358570
GlaxoSmithKline PLC Logo
A biopharmaceutical company developing vaccines and specialty medicines to prevent and treat disease.
United Kingdom GSK
GL Pharm Tech Corp. Logo
Develops improved drugs and generics, and licenses proprietary drug formulation technologies.
South Korea 204840
GNI  Group Ltd. Logo
Biopharma firm developing novel drugs for cancer and inflammatory diseases using genetics.
Japan 2160
Goodwill Pharma Plc Logo
Integrated pharma CDMO developing Rx/OTC meds, supplements & devices for CEE markets.
Hungary GWPH

Talk to a Data Expert

Have a question? We'll get back to you promptly.